Medisun Pharma Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
as on 25-12-2024
- Paid Up Capital ₹ 2.77 M
as on 25-12-2024
- Company Age 19 Year, 8 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 2.38 Cr
as on 25-12-2024
- Satisfied Charges ₹ 0.30 M
as on 25-12-2024
- Revenue 7.98%
(FY 2022)
- Profit 22.45%
(FY 2022)
- Ebitda 1.93%
(FY 2022)
- Net Worth 11.06%
(FY 2022)
- Total Assets 18.12%
(FY 2022)
About Medisun Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 2.77 M.
The company currently has active open charges totaling ₹2.38 Cr. The company has closed loans amounting to ₹0.30 M, as per Ministry of Corporate Affairs (MCA) records.
Ramesh Megde, Sunil Deshpande, Vandana Kunkikar, and One other member serve as directors at the Company.
- CIN/LLPIN
U24230MH2005PTC152826
- Company No.
152826
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
26 Apr 2005
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Nanded, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Medisun Pharma?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ramesh Megde  | Director | 26-Apr-2005 | Current |
| Sunil Deshpande | Director | 26-Apr-2005 | Current |
| Vandana Kunkikar | Whole-Time Director | 02-Jan-2006 | Current |
| Sachin Deshpande | Whole-Time Director | 26-Apr-2005 | Current |
Financial Performance of Medisun Pharma.
Medisun Pharma Private Limited, for the financial year ended 2022, experienced modest growth in revenue, with a 7.98% increase. The company also saw a substantial improvement in profitability, with a 22.45% increase in profit. The company's net worth Soared by an impressive increase of 11.06%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Medisun Pharma?
In 2018, Medisun Pharma had a promoter holding of 79.73% and a public holding of 20.27%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Idbi Bank Limited Creation Date: 11 Mar 2022 | ₹2.00 M | Open |
Idbi Bank Limited Creation Date: 07 Aug 2020 | ₹3.75 M | Open |
Others Creation Date: 04 May 2007 | ₹1.80 Cr | Open |
How Many Employees Work at Medisun Pharma?
Medisun Pharma has a workforce of 46 employees as of Mar 29, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Medisun Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Medisun Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
